BACKGROUND AND PURPOSE: NO produced by endothelial NOS is needed for normal vascular function. During diabetes, aging and hypertension, elevated levels of arginase can compete with NOS for available l-arginine, reducing NO and increasing superoxide (O(2) (.-)) production via NOS uncoupling. Elevated O(2) (.-) combines with NO to form peroxynitrite (ONOO(-)), further reducing NO. Oxidative species increase arginase activity, but the mechanism(s) involved are not known. Our study determined the mechanism involved in peroxynitrite and hydrogen peroxide-induced enhancement in endothelial arginase activity. We hypothesized that oxidative species increase arginase activity through PKC-activated RhoA/Rho kinase (ROCK) pathway. EXPERIMENTAL APPROACH: Arginase activity/expression was analysed in bovine aortic endothelial cells (BAEC) treated with an ONOO(-) generator (SIN-1) or H(2) O(2). Pretreatment with inhibitors of Rho kinase (Y-27632) or PKC (Gö6976) was used to investigate the mechanism involved in arginase activation. KEY RESULTS: Exposure to SIN-1 (25 µM, 24 h) or H(2) O(2) (25 µM, 8 h) increased arginase I expression and arginase activity (35% and 50%, respectively), which was prevented by ROCK inhibitor, Y-27632, PKC inhibitor, Gö6976 or siRNA to p115-Rho GEF. There was an early activation of p115-Rho GEF (SIN-1, 2 h; H(2) O(2), 1 h) and Rho A (SIN-1, 4 h; H(2) O(2), 1 h) that was prevented by using the PKC inhibitor. Exposure to SIN-1 and H(2) O(2 ) also reduced NOS activity, which was blocked by pretreatment with p115-RhoGEF siRNA. CONCLUSIONS AND IMPLICATIONS: Our data indicate that the oxidative species ONOO(-) and H(2) O(2) increase arginase activity/expression through PKC-mediated activation of RhoA/Rho kinase pathway.
BACKGROUND AND PURPOSE: NO produced by endothelial NOS is needed for normal vascular function. During diabetes, aging and hypertension, elevated levels of arginase can compete with NOS for available l-arginine, reducing NO and increasing superoxide (O(2) (.-)) production via NOS uncoupling. Elevated O(2) (.-) combines with NO to form peroxynitrite (ONOO(-)), further reducing NO. Oxidative species increase arginase activity, but the mechanism(s) involved are not known. Our study determined the mechanism involved in peroxynitrite and hydrogen peroxide-induced enhancement in endothelial arginase activity. We hypothesized that oxidative species increase arginase activity through PKC-activated RhoA/Rho kinase (ROCK) pathway. EXPERIMENTAL APPROACH: Arginase activity/expression was analysed in bovine aortic endothelial cells (BAEC) treated with an ONOO(-) generator (SIN-1) or H(2) O(2). Pretreatment with inhibitors of Rho kinase (Y-27632) or PKC (Gö6976) was used to investigate the mechanism involved in arginase activation. KEY RESULTS: Exposure to SIN-1 (25 µM, 24 h) or H(2) O(2) (25 µM, 8 h) increased arginase I expression and arginase activity (35% and 50%, respectively), which was prevented by ROCK inhibitor, Y-27632, PKC inhibitor, Gö6976 or siRNA to p115-Rho GEF. There was an early activation of p115-Rho GEF (SIN-1, 2 h; H(2) O(2), 1 h) and Rho A (SIN-1, 4 h; H(2) O(2), 1 h) that was prevented by using the PKC inhibitor. Exposure to SIN-1 and H(2) O(2 ) also reduced NOS activity, which was blocked by pretreatment with p115-RhoGEF siRNA. CONCLUSIONS AND IMPLICATIONS: Our data indicate that the oxidative species ONOO(-) and H(2) O(2) increase arginase activity/expression through PKC-mediated activation of RhoA/Rho kinase pathway.
Authors: Alia Shatanawi; Maritza J Romero; Jennifer A Iddings; Surabhi Chandra; Nagavedi S Umapathy; Alexander D Verin; Ruth B Caldwell; R William Caldwell Journal: Am J Physiol Cell Physiol Date: 2011-02-02 Impact factor: 4.249
Authors: Beth M Boulden; Julian D Widder; Jon C Allen; Debra A Smith; Ruaa N Al-Baldawi; David G Harrison; Sergey I Dikalov; Hanjoong Jo; Samuel C Dudley Journal: Free Radic Biol Med Date: 2006-06-03 Impact factor: 7.376
Authors: Claudia R Morris; Gregory J Kato; Mirjana Poljakovic; Xunde Wang; William C Blackwelder; Vandana Sachdev; Stanley L Hazen; Elliott P Vichinsky; Sidney M Morris; Mark T Gladwin Journal: JAMA Date: 2005-07-06 Impact factor: 56.272
Authors: Liming Jin; Zhekang Ying; Rob H P Hilgers; Jia Yin; Xueying Zhao; John D Imig; R Clinton Webb Journal: J Pharmacol Exp Ther Date: 2006-03-28 Impact factor: 4.030
Authors: Christian H Coyle; Luis J Martinez; Mitchell C Coleman; Douglas R Spitz; Neal L Weintraub; Khalid N Kader Journal: Free Radic Biol Med Date: 2006-03-23 Impact factor: 7.376
Authors: Sungwoo Ryoo; Christopher A Lemmon; Kevin G Soucy; Gaurav Gupta; Anthony R White; Daniel Nyhan; Artin Shoukas; Lewis H Romer; Dan E Berkowitz Journal: Circ Res Date: 2006-09-28 Impact factor: 17.367
Authors: Surabhi Chandra; David J R Fulton; Ruth B Caldwell; R William Caldwell; Haroldo A Toque Journal: Eur J Pharmacol Date: 2018-11-28 Impact factor: 4.432
Authors: Azza B El-Remessy; Huda E Tawfik; Suraporn Matragoon; Bindu Pillai; Ruth B Caldwell; R William Caldwell Journal: Exp Diabetes Res Date: 2010-11-01
Authors: Lin Yao; Surabhi Chandra; Haroldo A Toque; Anil Bhatta; Modesto Rojas; Ruth B Caldwell; R William Caldwell Journal: Cardiovasc Res Date: 2012-12-17 Impact factor: 10.787